Biotron, an Australian drug development company, has reported positive results from a Phase IIa trial that evaluated the efficacy of BIT225 in patients infected with the hepatitis C virus.

BIT225 specifically targets the p7 protein, which is essential to virus production and replication.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Preliminary analysis of trial data demonstrated that BIT225, an orally administered, small molecule drug, has good antiviral activity against the hepatitis C virus.

Patients receiving BIT225 in combination with interferon and ribavirin showed better reductions in hepatitis C virus levels than patients receiving standard of care treatment alone.

In the study, the drug also showed good tolerability and efficacy results.

The drug is also in development for treatment of HIV, with a Phase Ib/IIa trial currently underway, the company said.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact